RxDoctor Payments Data

Kristina Karanec, DO

Neurology · Grand Rapids, MINPI 1053503748

Payments from drug & device makers

$1,485in general payments, 2019–2025

Across 30 payments — averaging $49.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$958
  • Greenwich Biosciences, Inc.$262
  • SK Life Science, Inc.$98
  • Jazz Pharmaceuticals Inc.$54
  • Sunovion Pharmaceuticals Inc.$31
  • Eisai Inc.$23
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$1,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,485 in reported general payments places this provider in the 50th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$29,969
Medicare patients
157
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)34$148,448
TopamaxTopiramate41$79,979
BriviactBrivaracetam37$77,705
KeppraLevetiracetam35$62,846
VimpatLacosamide20$59,502
LamictalLamotrigine22$40,970
NayzilamMidazolam55$40,363
Oxtellar XrOxcarbazepine18$39,066
XcopriCenobamate33$36,051
FycompaPerampanel27$30,990
Vigabatrin13$28,902
Lacosamide213$21,927
Lamotrigine ErLamotrigine78$19,360
Levetiracetam349$14,719
Tegretol XrCarbamazepine19$13,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$958$177,569112 claims
SK Life Science, Inc.Xcopri$98$36,05133 claims
Eisai Inc.Fycompa$23$30,99027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 652 neurology providers in Michigan.

Other neurology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →